Ibrutinib D5 is the penta-deuterated form (in the terminal phenyl ring) of Ibrutinib (PCI-32765; Imbruvica), which is an approved anticancer drug acting as a covalent/irreversible and orally bioavailable Brutons tyrosine kinase (Btk) inhibitor with potential anti-cancer activity.

纯度：≥98%

CAS：1553977-17-5